文献速递免疫规划妇幼与学校卫生

MINHAI PCV13 在中国 7 月龄至 5 岁儿童中的 III 期临床试验

A phase 3 clinical trial of MINHAI PCV13 in Chinese children aged from 7 months to 5 years old.
PubMed 文献 · Vaccine · 2021-10-24

该随机双盲平行对照 III 期试验纳入 900 名 7 月龄至 5 岁中国儿童,以 Hib 结合疫苗为阴性对照,按 2:1 肌内注射,评价 MINHAI PCV13 的安全性及免疫原性。结果显示无 PCV13 相关严重不良事件,PCV13 组部分不良事件发生率高于 Hib 组但多为轻中度,全部 13 个血清型的 IgG 与 OPA 指标总体优于 Hib 组且差异多具统计学显著性,提示该疫苗可有效诱导肺炎球菌特异性抗体。

要点

  • MINHAI PCV13 在 7 月龄至 5 岁中国儿童中未发生疫苗相关严重不良事件。
  • PCV13 组部分不良事件发生率高于 Hib 组,但多为轻中度。
  • 全部 13 个血清型 IgG 与 OPA 指标总体优于对照,差异多具统计学显著性。

核心结论

  • MINHAI PCV13 在中国 7 月龄至 5 岁儿童中具有足够的免疫原性和安全性。

研究设计与样本

  • 随机、双盲、平行对照 III 期临床试验,共 900 名受试者。
  • 以 Hib 结合疫苗为阴性对照,PCV13 与 Hib 按 2:1 肌内注射。
  • 免疫前后采集血样检测血清型特异性抗多糖 IgG 与 OPA。

主要发现

  • 研究期间无 PCV13 相关严重不良事件发生。
  • PCV13 组若干不良事件发生率高于 Hib 组,但多为轻中度。
  • 全部 13 个血清型的 IgG 与 OPA 指标 PCV13 组总体优于 Hib 组,差异多具统计学显著性。

关键数值与推荐

  • 以 IgG 浓度 ≥ 0.35 μg/mL 的比例(IgG 阳性率)、IgG 几何平均浓度(GMC)、OPA 几何平均滴度(GMT)等指标评价免疫原性。

临床怎么用

  • 该试验为 MINHAI PCV13 在中国 7 月龄至 5 岁儿童中的使用提供了安全性与免疫原性证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pneumococcus lead to various kinds of invasive disease such as pneumonia, otitis media, meningitis, bacteremia and so on. It has been a great threat to children under 5. A new 13-valent pneumococcal conjugate vaccine (PCV13) with carrier tetanus toxoid and diphtheria toxoid was developed by MINHAI, aiming to prevent pneumococcus infection. In this study, we reported the safety and immunogenicity of MINHAI PCV13 in Chinese children aged from 7 months to 5 years old. METHODS: A randomized, double-blinded, parallelized phase III clinical trial was operated in 900 participants. Haemophilus influenzae type B conjugate vaccine (Hib) served as negative control. PCV13 and Hib were intramuscular injected to participants at a ratio of 2:1. Local and systemic adverse events (AEs) and severe adverse events (SAEs) were recorded to evaluate the safety of PCV13. Blood samples were collected before and after immunization for the detecting of serotype-specific anti-polysaccharide immunoglobulin (Ig)G and opsonophagocytosis assay (OPA). The proportion of IgG concentration ≥ 0.35 μg/mL (IgG positive rate), IgG geometric mean concentration (GMC), OPA geometric mean titer (GMT), and other indicators were analyzed to evaluate the immunogenicity of PCV13. RESULTS: During the study period, no PCV13 associated SAE happened. Incidences of several AEs in PCV13 groups were higher than the Hib groups, but most of them were mild or moderate. For all 13 serotypes, IgG and OPA indicators of the PCV13 groups were generally superior to the Hib groups, and the differences were mostly statistically significant, which indicates that MINHAI PCV13 can effectively induce pneumococcal specific antibody. CONCLUSION: The study demonstrates that MINHAI PCV13 has sufficient immunogenicity and safety in Chinese children aged from 7 months to 5 years old. CLINICAL TRIAL REGISTRATION: NCT02494999.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Liang Q, Li H, Chang X, et al. A phase 3 clinical trial of MINHAI PCV13 in Chinese children aged from 7 months to 5 years old. Vaccine. 2021. PMID: 34706841. doi:10.1016/j.vaccine.2021.09.047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。